IL-23

Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. As a small sample of novel agents demonstrating efficacy in PsA presented at ACR Convergence 2021, we have…

First, a quick recap of how we got here. Guselkumab, an IL-23p19-subunit inhibitor, was approved for moderate to severe plaque psoriasis in July 2017. With the success of DISCOVER 1 (D1) and…

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a…

The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis. I’…